The Bureau of Prisons said Friday it is investigating the conduct of notorious former hedge fund manager Martin Shkreli after a report he was using a cellphone from the New Jersey prison where he is serving a seven-year prison term.
The Wall Street Journal reported that Shkreli was using a cellular phone to help run a pharmaceutical company, now known as Phoenixus, that he helped found. Shkreli even used the phone to attempt to fire the company’s chief executive, The Journal reported.
“When there are allegations of misconduct, they are thoroughly investigated and appropriate action is taken if such allegations are proven true,” the bureau said in a statement. “This allegation is currently under investigation.”
Inmates found with a phone – a “greatest severity level” act – face a year in prison and a fine, the bureau said.
Most Read Stories
- Snohomish County man has the United States’ first known case of Wuhan coronavirus
- 5 of the Seattle area's most changed neighborhoods: We crunched the data on population, income, jobs
- 'We were before our time': Remembering the fight to change King County's namesake from a slave owner to a civil-rights leader VIEW
- Did the Seahawks make a mistake by letting Richard Sherman go?
- How white families with young children can work to undo racism
Shhkreli’s attorney, Benjamin Brafman, declined to comment.
Shkreli, 35, went from a rising star in the hedge fund world to Wall Street bad boy and felon. He was best known for raising the price of an AIDS drug by 5,000 percent and smirking through interviews and congressional appearances, beefing with rappers, reporters and almost anyone else in his path. Shkreli was repeatedly banned from Twitter.
He was arrested in 2015 and sentenced last year after a federal jury found he had defrauded investors in his hedge funds, including repeatedly lying to investors about major losses.
According to the Journal, Shkreli has not wasted much time since being imprisoned. He has made friends (“Krispy” and “D-Block”), cares for prison cats and continues to wield significant power over Phoenixus, a privately-held Swiss pharmaceutical company.
He estimates that the pharmaceutical company could be worth $3.7 billion by the time he is released, the Journal said.